Several newer diabetes medications outperform metformin for blood sugar control, weight loss, and organ protection, though “better” depends on what you need most. Metformin has been the default first-line treatment for type 2 diabetes for decades because it’s effective, cheap, and well-studied. But the landscape has shifted. The 2025 ADA Standards of Care now recommend newer drug classes as first-line options for people with cardiovascular disease, heart failure, or kidney disease, not just as add-ons to metformin.
GLP-1 Receptor Agonists for Blood Sugar and Weight
GLP-1 receptor agonists, the drug class that includes semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), lower blood sugar by mimicking a gut hormone that triggers insulin release after meals and slows digestion. They consistently produce greater reductions in both HbA1c and body weight than metformin alone.
The weight difference is substantial. In studies of adolescents and adults with type 2 diabetes, GLP-1 receptor agonists reduced BMI by about 5.1% over the study period, compared to just 0.59% for metformin. That translates to roughly 40 times more monthly BMI reduction. For adults who need to lose significant weight alongside managing blood sugar, this class of drug does both jobs in a way metformin simply cannot match.
GLP-1 drugs do cause nausea, vomiting, and other gut-related side effects, especially during the first weeks of treatment. Interestingly, people already taking metformin who add a GLP-1 drug don’t experience worse GI symptoms than those taking the GLP-1 alone. In fact, across four large clinical trials involving nearly 17,000 adults, people not on metformin were actually more likely to have GI problems and to discontinue their GLP-1 medication. This suggests that if you tolerate metformin well, combining it with a GLP-1 drug is a reasonable strategy rather than a guaranteed recipe for stomach trouble.
Tirzepatide: The Dual-Action Option
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) works on two gut hormone pathways simultaneously instead of just one. It activates both the GLP-1 receptor and a second receptor called GIP, which amplifies the blood sugar and weight loss effects beyond what single-action GLP-1 drugs achieve. In clinical trials, tirzepatide produced HbA1c reductions of up to 2.4% and weight loss averaging 12 to 25 pounds depending on the dose, outperforming every other injectable diabetes drug tested head-to-head.
The main barriers are cost and access. Tirzepatide is expensive without insurance coverage, and supply shortages have been common since its approval. For people whose primary concern is aggressive blood sugar control or significant weight loss, it currently represents the most potent single medication available.
SGLT2 Inhibitors for Heart and Kidney Protection
If your concern goes beyond blood sugar numbers, SGLT2 inhibitors (such as empagliflozin and dapagliflozin) offer something metformin does not: proven protection for the heart and kidneys. These drugs work by blocking sugar reabsorption in the kidneys, causing excess glucose to leave through urine. But their benefits extend well beyond that mechanism.
In a large UK population study, people taking an SGLT2 inhibitor had a 25% lower risk of a composite cardiovascular event (heart attack, stroke, or cardiovascular death) compared to those on metformin alone. The kidney protection was even more striking: a 45% reduction in the risk of severe kidney disease. Stroke risk dropped by 49%. All-cause mortality fell by 44%. Heart attack risk, however, was not significantly different between the two groups.
The 2025 ADA guidelines now position SGLT2 inhibitors as the preferred first-line choice, ahead of metformin, for anyone with type 2 diabetes who also has heart failure, chronic kidney disease, or established cardiovascular disease. For heart failure specifically, SGLT2 inhibitors are recommended to reduce hospitalizations and improve quality of life regardless of whether ejection fraction is preserved or reduced.
When Metformin Still Makes Sense
For a person with newly diagnosed type 2 diabetes, no cardiovascular disease, no kidney problems, and no urgent need for weight loss, metformin remains a solid choice. It lowers HbA1c by roughly 1 to 1.5%, costs a few dollars a month as a generic, and has decades of safety data. It also carries a low risk of hypoglycemia, which matters for people managing diabetes with diet and lifestyle changes alongside medication.
The GI side effects that make some people abandon metformin (diarrhea, nausea, cramping) often improve with the extended-release formulation or by increasing the dose gradually. But for those who genuinely cannot tolerate it, the alternatives above are not just substitutes. They’re often upgrades in specific ways.
Berberine: A Natural Alternative With Limits
Berberine, a compound found in several plants, sometimes gets promoted online as a “natural metformin.” There is some clinical evidence behind this claim, though it’s modest. In a randomized trial of people with prediabetes, berberine reduced HbA1c by 0.31% over 12 weeks compared to 0.28% for metformin, a statistically significant but clinically small difference. Both performed similarly for basic blood sugar management in that early-stage population.
The key limitation is that berberine lacks the large-scale, long-term outcome data that metformin and the newer drug classes have. No major trial has shown it reduces heart attacks, strokes, or kidney disease progression. It may be a reasonable option for someone with prediabetes or mild insulin resistance who prefers a supplement-based approach, but it is not a substitute for prescription medications in someone with established type 2 diabetes or organ complications.
How to Think About “Better”
The right answer depends on what you’re optimizing for. If your priority is weight loss alongside blood sugar control, GLP-1 receptor agonists and tirzepatide clearly outperform metformin. If you have heart failure or kidney disease, SGLT2 inhibitors offer life-extending benefits that metformin does not. If you want the cheapest effective option with the longest safety track record, metformin is hard to beat.
Many people end up on a combination. Metformin as a low-cost foundation, with an SGLT2 inhibitor or GLP-1 drug added for the specific benefits those classes provide. The newer medications aren’t always replacements for metformin. They’re often partners, each covering a gap the other leaves open.